Y Intercept Hong Kong Ltd Invests $92,000 in Werewolf Therapeutics, Inc. $HOWL

Y Intercept Hong Kong Ltd purchased a new stake in shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 84,421 shares of the company’s stock, valued at approximately $92,000. Y Intercept Hong Kong Ltd owned approximately 0.19% of Werewolf Therapeutics at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in HOWL. Nuveen LLC purchased a new position in Werewolf Therapeutics in the 1st quarter valued at about $71,000. AQR Capital Management LLC purchased a new stake in shares of Werewolf Therapeutics during the first quarter worth about $79,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Werewolf Therapeutics by 33.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock worth $93,000 after acquiring an additional 23,852 shares in the last quarter. MPM Bioimpact LLC lifted its stake in shares of Werewolf Therapeutics by 0.9% in the first quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock worth $2,341,000 after acquiring an additional 20,799 shares in the last quarter. Finally, MPM Asset Management LLC boosted its holdings in Werewolf Therapeutics by 0.6% in the first quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after purchasing an additional 25,688 shares during the last quarter. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Price Performance

Shares of NASDAQ HOWL opened at $1.15 on Monday. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73. The company has a market capitalization of $55.82 million, a price-to-earnings ratio of -0.71 and a beta of 0.73. Werewolf Therapeutics, Inc. has a twelve month low of $0.60 and a twelve month high of $2.39. The business has a 50 day simple moving average of $1.60 and a 200-day simple moving average of $1.33.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. As a group, equities research analysts expect that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on HOWL. Zacks Research upgraded Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 16th. JMP Securities decreased their price target on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research report on Thursday, August 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Citigroup reiterated a “buy” rating on shares of Werewolf Therapeutics in a research note on Monday, August 25th. Finally, Bank of America decreased their price objective on shares of Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a report on Monday, August 25th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

Insider Activity

In related news, major shareholder Bioventures 2014 L.P. Mpm sold 140,488 shares of the business’s stock in a transaction dated Tuesday, November 4th. The shares were sold at an average price of $1.22, for a total transaction of $171,395.36. Following the completion of the sale, the insider owned 6,007,122 shares of the company’s stock, valued at $7,328,688.84. This represents a 2.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Luke Evnin sold 90,164 shares of the stock in a transaction dated Tuesday, November 4th. The stock was sold at an average price of $1.22, for a total transaction of $110,000.08. Following the sale, the director owned 3,853,195 shares in the company, valued at approximately $4,700,897.90. This trade represents a 2.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 2,150,286 shares of company stock valued at $2,995,317. Company insiders own 23.60% of the company’s stock.

Werewolf Therapeutics Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.